| [1] |
Shehata AMF, Aldesoky AI, Gohar SF.Plasma fibrinogen level as possible prognostic biomarker in diffuse large B-cell lymphoma [J]．Hematology，2019，24(1): 103-107.
|
| [2] |
Ohno H, Nakagawa M, Kishimori C, et al. Diffuse large B-cell lymphoma carrying t(9；14)(p13；q32)/PAX5-immunoglobulin heavy chain gene is characterized by nuclear positivity of MUM1 and PAX5 by immunohistochemistry[J]．Hematol Oncol，2020，18(10): 2716-2720.
|
| [3] |
Grimm KE, O'Malley DP.Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues [J]. Ann Diagn Pathol，2019(38): 6-10.
|
| [4] |
Yin W, Xia X, Wu M, et al. The impact of BCL-2/MYC protein expression and gene abnormality on primary central nervous system diffuse large B-cell lymphoma [J]．Int J Clin Exp Pathol，2019，12(6): 2215-2223.
|
| [5] |
Ball MK, Morris JM, Wood AJ，et al.Ventricle-predominant primary CNS lymphomas：clinical，radiological and pathological evaluation of five cases and review of the literature[J]．Brain Tumor Pathol，2020，37(1): 22-30.
|
| [6] |
Ghali MGZ, Samkari A, Hou JS，et al.Synchronous primary central nervous system and pulmonary lymphoma in a 7-year-old female with unspecified T-cell immunodeficiency[J]．Pediatr Neurosurg，2018，53(5): 311-316.
|
| [7] |
Ferreri AJM, Holdhoff M, Nayak L，et al.Evolving treatments for primary central nervous system lymphomae[J]．Am Soc Clin Oncol Educ Book，2019(39): 454-466.
|
| [8] |
Chukwueke UN, Nayak L．Central nervous system lymphoma[J]．Hematol Oncol Clin North Am，2019，33(4): 597-611.
|
| [9] |
Zajdel M, Rymkiewicz G, Sromek M，et al.Tumor and cerebrospinal fluid micro RNAs in primary central nervous system lymphomas[J]．Cancers (Basel)，2019，11(11): 1647-1650.
|
| [10] |
Dai X, Yao J, Zhong Y，et al.Preparation and characterization of Fe3O4 MTX magnetic nanoparticles for thermochemotherapy of primary central nervous system lymphoma in vitro and in vivo[J]. Int J Nanomedicine，2019(14): 6947-9663.
|
| [11] |
Chatterjee S, Angelov L, Ahluwalia MS，et al.Epstein-Barr virus-associated primary central nervous system lymphoma in a patient with diffusecutaneous systemic sclerosis on long-term mycophenolate mofetil[J]．Joint Bone Spine，2020，87(2): 163-166.
|
| [12] |
Cao S, Rohani P, Nazarian RM, et al. A 65-year-old male with primary central nervous system diffuse large B-cell lymphoma on nivolumab with oral mucositis and targetoid plaques[J]．Dermatopathology (Basel)，2017，4(1-4): 13-17.
|
| [13] |
Kaulen LD, Galluzzo D, Hui P, et al. Prognostic markers for immunodeficiency-associated primary central nervous systemlymphoma[J]．J Neurooncol，2019，144(1): 107-115.
|
| [14] |
Batchelor TT.Primary central nervous system lymphoma：a curable disease[J]．Hematol Oncol，2019，37 (Suppl): 15-18.
|
| [15] |
Zheng M, Perry AM, Bierman P，et al.Frequency of MYD88 and CD79B mutations，and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma[J]．Neuropathology，2017，37(6): 509-516.
|
| [16] |
Alame M, Pirel M, Costes-Martineau V，et al.Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas[J]．Virchows Arch，2019(10): 1007-1009.
|
| [17] |
Mori Y, Yamamoto K, Ohno A，et al.Primary central nervous system lymphoma with peripheral nerve involvement：case report[J]．Cureus，2019，11(9): 5675-5680.
|
| [18] |
Qualls D, Abramson JS.Advances in risk assessment and prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma[J]．Haematologica，2019，104(1): 25-34.
|
| [19] |
Makino K, Nakamura H, Shinojima N, et al. BCL2 expression is associated with a poor prognosis independent of cellular origin in primary central nervous system diffuse large B-cell lymphoma[J]．J Neuroonco，2018，140(1): 115-121.
|
| [20] |
冯强，王文洋，卜凡，等．原发性甲状腺弥漫性大B淋巴细胞瘤的诊断学特征[J/CD]．中华诊断学电子杂志，2017，5(2): 124-127.
|